Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial.

MLA

Puig, Noemi, et al. “Lenalidomide and Dexamethasone with or without Clarithromycin in Patients with Multiple Myeloma Ineligible for Autologous Transplant: A Randomized Trial.” Blood Cancer Journal, vol. 11, no. 5, May 2021, p. 101. EBSCOhost, https://doi.org/10.1038/s41408-021-00490-8.

APA

Puig, N., Hernández, M. T., Rosiñol, L., González, E., de Arriba, F., Oriol, A., González-Calle, V., Escalante, F., de la Rubia, J., Gironella, M., Ríos, R., García-Sánchez, R., Arguiñano, J. M., Alegre, A., Martín, J., Gutiérrez, N. C., Calasanz, M. J., Martín, M. L., Couto, M. D. C., … Mateos, M.-V. (2021). Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 11(5), 101. https://doi.org/10.1038/s41408-021-00490-8

Chicago

Puig, Noemi, Miguel T Hernández, Laura Rosiñol, Esther González, Felipe de Arriba, Albert Oriol, Verónica González-Calle, et al. 2021. “Lenalidomide and Dexamethasone with or without Clarithromycin in Patients with Multiple Myeloma Ineligible for Autologous Transplant: A Randomized Trial.” Blood Cancer Journal 11 (5): 101. doi:10.1038/s41408-021-00490-8.